AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25841539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonsynbiotic‐containing acidified milk drink)
Number of subjects: 149
Study 23297395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tea tree oil (TTO) body wash
Number of subjects: 391
Study 23297395 — intervention group
Group type: COMPARATOR
Intervention: Johnson's Baby Softwash (JBS)
Number of subjects: 391
Study 21338531 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating the Blues program (CCBT)
Number of subjects: 510
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin noradrenaline reuptake inhibitors
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied capsaicin (8%)
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 0
Study 19741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Number of subjects: 0
Study 17952153 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid, non-steroidal anti-inflammatory drugs, and COX-2 inhibitors
Number of subjects: 0
Study 17952153 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood testing (FOBT)
Number of subjects: 0
Study 17952153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic screening
Number of subjects: 0
Study 17952153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy screening
Number of subjects: 0
Study 17952153 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy screening
Number of subjects: 0
Study 15184094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory focus
Number of subjects: 82
Study 15184094 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect focus
Number of subjects: 82
Study 15184094 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study 10831773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 92
Study 10831773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 9478065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid and salt supplementation (FSS) during hypokinesia (HK)
Number of subjects: 30
Study 9478065 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupplemented hypokinetic subjects (UHS)
Number of subjects: 30
Study 9478065 — intervention group
Group type: COMPARATOR
Intervention: Control group (continuous exercise of 13.8 km/day)
Number of subjects: 30
Study 1334126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota colostrum (20 ml per day for 2 weeks)
Number of subjects: 20
Study 1334126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota colostrum (every other day)
Number of subjects: 20
Study 1334126 — intervention group
Group type: COMPARATOR
Intervention: Control (no Rota colostrum)
Number of subjects: 20
Study 1334126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota colostrum (after symptoms appeared)
Number of subjects: 20
Study 6537445 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug education course
Number of subjects: 0
Study 6537445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30639756 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness severity and unpleasantness measured on a 0-100 mm visual analogue scale (VAS)
Number of subjects: 265
Study 30639756 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness severity and unpleasantness assessed in the morning and evening over eight days
Number of subjects: 265
Study 30639756 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors evaluated included age, sex, diagnosis, morning/evening assessment, modified Medical Research Council breathlessness score, morphine treatment
Number of subjects: 265
Study 29279155 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mgI/kg at 120‐kV tube voltage setting (600‐120 group)
Number of subjects: 120
Study 29279155 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mgI/kg at 80kV (600‐80 group)
Number of subjects: 120
Study 29279155 — intervention group
Group type: EXPERIMENTAL
Intervention: 360mgI/kg at 80kV (360‐80 group)
Number of subjects: 120
Study 27411273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric anterolateral thigh flap
Number of subjects: 74
Study 27411273 — intervention group
Group type: COMPARATOR
Intervention: Series-wound flaps
Number of subjects: 74
Study 14621732 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-AZA combination treatment
Number of subjects: 21
Study 14621732 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 21
Study 14621732 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 21
Study 21853391 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based training (SL group)
Number of subjects: 24
Study 21853391 — intervention group
Group type: COMPARATOR
Intervention: Traditional training in the OR (OR group)
Number of subjects: 24
Study 20511085 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air gowns
Number of subjects: 150
Study 20511085 — intervention group
Group type: COMPARATOR
Intervention: Warmed cotton blankets
Number of subjects: 150
Study 18456064 — intervention group
Group type: EXPERIMENTAL
Intervention: Charité (Depuy) disc prosthesis
Number of subjects: 32
Study 18456064 — intervention group
Group type: COMPARATOR
Intervention: Intersomatic KLA cage (Scient'x)
Number of subjects: 32
Study 15725309 — intervention group
Group type: EXPERIMENTAL
Intervention: (81m)Kr SPECT
Number of subjects: 38
Study 14622490 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned midwifery-led postnatal care
Number of subjects: 2064
Study 14622490 — intervention group
Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 2064
Study 11129615 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA with bupivacaine 0.125%, sufentanil 0.75 microgram/ml and epinephrine 1/800.000 without a basal rate
Number of subjects: 80
Study 11129615 — intervention group
Group type: COMPARATOR
Intervention: Epidural PCA with bupivacaine 0.125%, sufentanil 0.75 microgram/ml and epinephrine 1/800.000 with a basal rate of 3 ml/hr
Number of subjects: 80
Study 8750479 — intervention group
Group type: EXPERIMENTAL
Intervention: New anticancer therapies
Number of subjects: 0
Study 8750479 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial studies
Number of subjects: 0
Study 8750479 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual approaches by clinical investigators
Number of subjects: 0
Study 1724541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-rate ANF infusion (0.25 micrograms/min)
Number of subjects: 16
Study 1724541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate ANF infusion (2.0 micrograms/min)
Number of subjects: 16
Study 1724541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 477026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous modified immune serum globulin (M‐ISG)
Number of subjects: 20
Study 477026 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular immune serum globulin (ISG)
Number of subjects: 20
Study 31964414 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step feedback report design method (refinement of measures, data, and display)
Number of subjects: 13
Study 30531397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 6
Study 30531397 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.045 mg/kg)
Number of subjects: 6
Study 27119222 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (six 1-hour sessions)
Number of subjects: 98
Study 27119222 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group for 12 months)
Number of subjects: 98
Study 25562479 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable contact lenses (nelfilcon A, DAILIES AquaComfort Plus)
Number of subjects: 110
Study 25562479 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 110
Study 23127169 — intervention group
Group type: EXPERIMENTAL
Intervention: LED group (625‐635 nm, maximum power density: 2000 mW/cm(2))
Number of subjects: 16
Study 23127169 — intervention group
Group type: EXPERIMENTAL
Intervention: Photosensitizer group (tolouidine blue O, 0.1 mg/ml)
Number of subjects: 16
Study 23127169 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD group (photosensitizer and LED)
Number of subjects: 16
Study 23127169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjunctive treatment)
Number of subjects: 16
Study 20926751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonapofylline (0.2-375 mg)
Number of subjects: 0
Study 20926751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonapofylline (in females)
Number of subjects: 0
Study 20926751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonapofylline (with food)
Number of subjects: 0
Study 20926751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonapofylline (single dose)
Number of subjects: 0
Study 19018798 — intervention group
Group type: EXPERIMENTAL
Intervention: Subendocardial viability index (SVI)
Number of subjects: 38
Study 19018798 — intervention group
Group type: EXPERIMENTAL
Intervention: SVI calculated assuming zero LVEDP
Number of subjects: 38
Study 19018798 — intervention group
Group type: EXPERIMENTAL
Intervention: DT/ST ratio
Number of subjects: 38
Study 19018798 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDP
Number of subjects: 38
Study 19018798 — intervention group
Group type: COMPARATOR
Intervention: Aortic pressure
Number of subjects: 38
Study 17681360 — intervention group
Group type: EXPERIMENTAL
Intervention: GPO dihydroartemisinin tablet formulation, 200mg single oral dose
Number of subjects: 24
Study 17681360 — intervention group
Group type: COMPARATOR
Intervention: Dafra dihydroartemisinin tablet formulation, 200mg single oral dose
Number of subjects: 24
Study 17681360 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of DHA (both formulations)
Number of subjects: 24
Study 17681360 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of DHA (both formulations)
Number of subjects: 24
Study 16649968 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (1 mg/kg i.m. every 4 weeks for 6 months) + Letrozole (2.5 mg/day orally for 12 months)
Number of subjects: 17
Study 16649968 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (1 mg/kg i.m. every 4 weeks for 6 months) + Placebo
Number of subjects: 17
Study 16649968 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate + Letrozole
Number of subjects: 17
Study 16649968 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate + Placebo
Number of subjects: 17
Study 12562453 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg/day for 5 days with 3 mg budesonide controlled-release capsules on day 5
Number of subjects: 13
Study 12562453 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days with 3 mg budesonide controlled-release capsules on day 5
Number of subjects: 13
Study 10418761 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 80 mg artemether orally
Number of subjects: 88
Study 10418761 — intervention group
Group type: COMPARATOR
Intervention: 4 x 80‐480 mg co‐artemether
Number of subjects: 88
Study 8541359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 0
Study 8541359 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 0
Study 2130823 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-rich diet (1,142.0 +/- 225 mg/day)
Number of subjects: 430
Study 2130823 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (438 +/- 118 mg/day)
Number of subjects: 430
Study 2130823 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-rich diet (in hypomagnesemic patients)
Number of subjects: 430
Study 2130823 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (in hypomagnesemic patients)
Number of subjects: 430
Study 374401 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 15
Study 374401 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 15
Study 28648880 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated biofeedback therapy
Number of subjects: 40
Study 28648880 — intervention group
Group type: COMPARATOR
Intervention: Non-animated biofeedback therapy
Number of subjects: 40
Study 27286183 — intervention group
Group type: EXPERIMENTAL
Intervention: Single set of 30 s (SS)
Number of subjects: 66
Study 27286183 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets of 30 s (MS)
Number of subjects: 66
Study 25001960 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone response following the Trier Social Stress Test (TSST)
Number of subjects: 85
Study 25001960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower basal cortisol
Number of subjects: 85
Study 22474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 47
Study 22474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 47
Study 22474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachibana‐Ryojutsu
Number of subjects: 47
Study 20526200 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-year continuous estrogen-plus-progestin use
Number of subjects: 0
Study 20526200 — intervention group
Group type: COMPARATOR
Intervention: Dynamic treatment regimen (take hormone therapy until certain adverse events become apparent, then stop)
Number of subjects: 0
Study 20526200 — intervention group
Group type: COMPARATOR
Intervention: No use of hormone therapy
Number of subjects: 0
Study 18465110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with electrical stimulation
Number of subjects: 92
Study 18465110 — intervention group
Group type: COMPARATOR
Intervention: Mock TENS (placebo)
Number of subjects: 92
Study 16104901 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-101 (high-dose oral calcitriol) combined with docetaxel
Number of subjects: 0
Study 16104901 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with docetaxel
Number of subjects: 0
Study 14651247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bent-handled long-handled sponge
Number of subjects: 38
Study 14651247 — intervention group
Group type: COMPARATOR
Intervention: Straight-handled long-handled sponge
Number of subjects: 38
Study 10368039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation during radiotherapy sessions
Number of subjects: 208
Study 10368039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation during all radiotherapy sessions
Number of subjects: 208
Study 10368039 — intervention group
Group type: COMPARATOR
Intervention: Breathing air (control group)
Number of subjects: 208
Study 7575311 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean BAC = 0.037%)
Number of subjects: 12
Study 7575311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7575311 — intervention group
Group type: COMPARATOR
Intervention: Alcohol and Placebo
Number of subjects: 12
Study 2265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 15
Study 2265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 15
Study 2265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 15
Study 2265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, Enflurane, Isoflurane at 1.25 MAC
Number of subjects: 15
Study 2265047 — intervention group
Group type: COMPARATOR
Intervention: Halothane, Enflurane, Isoflurane
Number of subjects: 15
Study 6109345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofisopam (100 mg single dose)
Number of subjects: 12
Study 6109345 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg single dose)
Number of subjects: 12
Study 6109345 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg) + Ethanol (0.8 g/kg)
Number of subjects: 12
Study 6109345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6109345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofisopam (100 + 50 + 50 + 100 mg repeated doses)
Number of subjects: 12
Study 31839705 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 µg
Number of subjects: 378
Study 31839705 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 µg
Number of subjects: 378
Study 31839705 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 378
Study 27566597 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR)
Number of subjects: 212
Study 27566597 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 212
Study 27566597 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR) and Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 212
Study 25680727 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 keV Mono+
Number of subjects: 44
Study 25680727 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 keV Mono+
Number of subjects: 44
Study 25680727 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 keV Mono+
Number of subjects: 44
Study 25680727 — intervention group
Group type: COMPARATOR
Intervention: M_0.3 (30% 80 kV)
Number of subjects: 44
Study 25680727 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-to-noise ratio (CNR) at 40 keV
Number of subjects: 44
Study 23364608 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0101
Number of subjects: 2
Study 21085029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal locking plate
Number of subjects: 32
Study 21085029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal nonlocking plate
Number of subjects: 32
Study 21085029 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 32
Study 21085029 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar nonlocking plate
Number of subjects: 32
Study 19563641 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance/impact loading exercise
Number of subjects: 195
Study 19563641 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance/cardiovascular exercise
Number of subjects: 195
Study 19563641 — intervention group
Group type: COMPARATOR
Intervention: Usual care/delayed exercise
Number of subjects: 195
Study 17318527 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nimodipine (60 mg tablet/suspension at 4-h intervals)
Number of subjects: 17
Study 17318527 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nimodipine (2 mg/h continuous infusion)
Number of subjects: 17
Study 15241347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 300 mg twice daily
Number of subjects: 15
Study 15241347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10832772 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (2 IU/kg)
Number of subjects: 56
Study 10832772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9351614 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg
Number of subjects: 46
Study 9351614 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone 250 microg
Number of subjects: 46
Study 9351614 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of salmeterol and fluticasone
Number of subjects: 46
Study 9351614 — intervention group
Group type: COMPARATOR
Intervention: healthy control subjects
Number of subjects: 46
Study 8183178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) (100 IU daily) plus oral calcium
Number of subjects: 30
Study 8183178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3963018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg total daily dose, administered four times a day)
Number of subjects: 57
Study 3963018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg total daily dose, administered twice a day)
Number of subjects: 57
Study 3963018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 57
Study 3963018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (up to 300 mg per day)
Number of subjects: 57
Study 3963018 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 57
Study 31137095 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B1 (sound therapy for normal to mild hearing loss)
Number of subjects: 56
Study 31137095 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A2 (sound therapy for moderate to profound hearing loss)
Number of subjects: 56
Study 30292867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution cameras and object-detection algorithm for seatbelt enforcement; capacity trainings for law enforcement; infrastructure renovation; social marketing campaigns.
Number of subjects: 77641
Study 27895466 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐519 (25, 50, 100, 200, or 400 mg)
Number of subjects: 40
Study 27895466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24763877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic accessory-pathway ablation
Number of subjects: 110